广州多浦乐电子科技股份有限公司2025年度报告详细解读

核心要点与投资者须知

• 无损检测行业领军者：公司专注于工业无损检测设备的研发、生产和销售，产品涵盖超声检测设备、超声换能器、自动化检测系统等，广泛应用于特种设备、轨道交通、航空航天、能源电力、钢铁冶金、新能源汽车、半导体等多个关键行业。
• 业绩强劲增长：2025年营业收入达2.26亿元，同比增长39.24%。归属于上市公司股东的净利润为6649万元，同比增长28.85%。经营活动现金流净额同比增长75.78%，财务表现持续向好。
• 利润分配方案：以6190万股为基数，每10股派发现金红利1.08元（含税），并以资本公积金每10股转增4.5股，体现公司对股东回报的重视。
• 重大业务扩展：公司获得广东省生态环境厅批复，正式进入工业射线检测行业，经营范围将新增“研制、生产、销售工业X射线设备及有关设备”。已规划2D（DR）到3D（CT）及更高维度射线检测产品矩阵，核心产品预计2026年内完成并交付。
• 技术创新与产品迭代：推出新一代便携式超声相控阵全聚焦仪NovaScan V3（64-128阵元，发射电压最高200V，带宽0.18MHz~27MHz），轻便型NovaScan L3，256-256超声相控阵板卡及多款自动化检测系统。超声换能器高端定制能力强，涵盖工业及医疗领域。
• 股权激励与管理层变动：实施限制性股票激励计划（92万股授予72人），董事会、管理层完成换届，取消监事会，完善公司治理结构。
• 海外及子公司布局：2025年设立欧洲、中东子公司、创新子公司及检测子公司，并投资意领科技（持股10%），杭州循启增资至1500万元，全球化和多元化布局加速。

详细解读

主营业务与产品体系

多浦乐以超声无损检测为核心，形成了从换能器、扫查装置到便携式及自动化检测系统的完整产业链。无损检测可在不破坏被检测对象的情况下，定位、测量材料或结构异常，为工业质量与安全提供保障，被誉为“工业医生”。公司产品已深度应用于石化运输管线、航空航天装备、高铁轮轴、核电站压力容器、新能源汽车动力电池等高端场景。

进军射线检测领域

2025年12月，公司获得广东省生态环境厅批复，正式踏入工业射线检测行业。射线检测产品规划覆盖2D（DR）、3D（CT）及更高维度，涵盖离线与在线机台，支持多模式成像（2D、2.5D、平面CT 3D、锥束CT 3D），可满足PCB、半导体、航空航天、军工、汽车、新能源电池等多元化需求。首批定制设备预计2026年上半年交付，射线检测技术和专利布局正在推进。

产品创新与技术突破

• 便携式超声相控阵检测仪：主要产品NovaScan系列，支持全聚焦成像与高性能检测。
• 全聚焦检测仪：通过FMC捕捉法与TFM算法实现精准缺陷成像。NovaScan V3性能大幅提升，适用于更广泛检测场景。
• 板卡检测设备：板卡式设计，取消传统交互方式，提升成像能力，支持二次开发。
• 自动化检测设备：集成机械传动、自动化控制，实现智能化无损检测，产品覆盖液冷水冷板、棒材、钢板、半导体硅片等多领域。
• 超声换能器：批量生产复合材料换能器，具备高端定制能力，产品覆盖工业、医疗领域（如消化道、呼吸道超声内镜换能器、IVUS、RCA换能器）。

财务表现

业绩持续增长，净资产达15.62亿元，同比增长3.99%。加权平均净资产收益率4.35%。季度收入与利润均表现稳健，第四季度贡献最大。

股东结构与重要股权信息

• 主要股东：蔡庆生持股39.68%，纪轩荣6.86%，厦门融昱佳弘投资7.03%，广州悦生泰达3.63%。
• 股权激励计划：授予限制性股票92万股，激励对象72人，授予价30.55元/股，推动管理层与公司利益绑定。

公司治理及管理层变动

• 董事会、管理层换届完成，第三届董事会由7人组成（3名独立董事），职工代表董事选举完成。
• 取消监事会，相关职权由董事会审计委员会行使，章程及制度同步修订，治理结构更为规范。

全球化与子公司布局

• 2025年成立欧洲全资子公司（2.5万欧元）、中东控股子公司（24万迪拉姆）、创新合资公司、检测子公司，杭州循启增资至1500万元。
• 投资意领科技1200万港币，持股10%，拓展海外科技布局。

投资者关注的潜在价格敏感事项

• 工业射线检测领域扩张：正式进入射线检测行业，产品矩阵研发推进，预计2026年内核心产品交付。此举将显著拓宽公司业务边界，提升未来收入与利润增长潜力。
• 业绩持续高增长：营业收入、净利润、现金流均大幅提升，显示公司核心竞争力和市场需求强劲。
• 股权激励与治理优化：限制性股票激励计划有助于稳定和激励核心团队，治理结构优化提升公司透明度与效率。
• 全球化布局加速：欧洲、中东等子公司设立及海外投资，带动公司国际化进程，打开新市场空间。

总结

广州多浦乐电子科技股份有限公司2025年年度报告展示了公司在无损检测和新兴射线检测领域的持续研发创新、财务业绩的强劲增长、治理结构优化与全球化战略布局。公司正式进军射线检测行业及重大产品研发进展，业绩持续高增长，股权激励实施、管理层换届和国际化扩张，这些均为投资者高度关注且可能影响公司股价的重大事项。

投资者需特别关注公司射线检测领域的产品交付进展、业绩持续增长、治理结构变革及全球化布局，这些将成为未来公司价值提升的关键驱动因素。

免责声明

本文内容基于公司年度报告摘要，旨在为投资者提供参考信息。非投资建议，投资者请结合自身情况谨慎决策，关注公司公告及相关风险。

英文版：

Detailed Analysis of Guangzhou Doppler Electronics Technology Co., Ltd. 2025 Annual Report

Key Points & Investor Essentials

• Industry Leader in Nondestructive Testing: The company specializes in R&D, manufacturing, and sales of industrial nondestructive testing equipment, covering ultrasonic testing devices, transducers, automated systems, widely applied across special equipment, rail transit, aerospace, energy, steel, new energy vehicles, semiconductors, etc.
• Strong Performance Growth: 2025 revenue reached RMB 225.6 million, up 39.24%. Net profit attributable to shareholders was RMB 66.5 million, up 28.85%. Net cash flow from operations surged 75.78% year-on-year, showing robust financials.
• Dividend & Bonus Issue Plan: Based on 61.9 million shares, a cash dividend of RMB 1.08 per 10 shares (tax included) will be paid, plus a bonus issue of 4.5 shares per 10 shares via capital reserve, demonstrating commitment to shareholder returns.
• Major Business Expansion: Approved by Guangdong Environmental Protection Department to officially enter the industrial X-ray testing sector; business scope will add “R&D, production, sales of industrial X-ray equipment.” Full product matrix from 2D (DR) to 3D (CT) and higher dimensions planned, with core products scheduled for delivery in 2026.
• Technological Innovation: New products launched including NovaScan V3 portable phased array full-focus instrument (64-128 channels, up to 200V, 0.18MHz~27MHz bandwidth), NovaScan L3, miniaturized 256-256 phased array board, and various automated systems. Strong custom transducer capability for both industrial and medical markets.
• Equity Incentives & Management Changes: Restrictive stock incentive plan (920,000 shares to 72 people); board and management newly elected; supervisory board cancelled, improved corporate governance.
• Overseas & Subsidiary Expansion: 2025 saw establishment of subsidiaries in Europe, Middle East, and domestic innovation/testing entities; invested HKD 12 million in Yiling Tech (10% stake); Hangzhou Xunqi capital increased to RMB 15 million; globalization and diversification accelerated.

In-depth Analysis

Main Business & Product Chain

Doppler focuses on ultrasonic nondestructive testing, forming a full industrial chain from transducers, scanning devices to portable and automated systems. Nondestructive testing detects anomalies without damaging objects, essential for industrial quality & safety, known as “industrial doctors”. Products are deeply applied in petrochemical pipelines, aerospace, high-speed rail axles, nuclear power vessels, new energy vehicle batteries, etc.

Entry into X-ray Testing Field

In December 2025, received approval to officially enter industrial X-ray testing. Planned product matrix covers 2D (DR), 3D (CT), and higher dimensions, including offline/online machines, multi-mode imaging (2D, 2.5D, planar CT 3D, cone-beam CT 3D), meeting needs of PCB, semiconductors, aerospace, military, automotive, batteries, etc. First custom devices expected to be delivered in H1 2026, with R&D and patent layout underway.

Product Innovation & Technology Breakthroughs

• Portable ultrasonic phased array instrument: NovaScan series, supporting full-focus imaging and high-performance detection.
• Full-focus instrument: FMC acquisition and TFM algorithm for precise defect imaging; NovaScan V3 greatly improved, covering broader scenarios.
• Board-based detection devices: No traditional panels, enhanced imaging, supports secondary development.
• Automated detection devices: Integrates mechanical transmission & control for intelligent testing; covers liquid cooling plates, rods, steel plates, semiconductor wafers, etc.
• Ultrasonic transducers: Mass-produced composite material, strong custom capability, covering industrial and medical (e.g., endoscopic, IVUS, RCA transducers).

Financial Performance

Consistent growth; net assets RMB 1.56 billion, up 3.99%. ROAE 4.35%. Quarterly income/profits steady, Q4 most significant.

Shareholder Structure & Key Equity Info

• Major shareholders: Cai Qingsheng owns 39.68%, Ji Xuanrong 6.86%, Xiamen Rongyu Jiahong Investment 7.03%, Guangzhou Yueshengtai Da 3.63%.
• Equity incentive plan: 920,000 shares granted to 72 key personnel at RMB 30.55/share, enhancing management alignment.

Corporate Governance & Management Changes

• Board, management re-elected, new board of 7 (3 independents), employee director elected.
• Supervisory board cancelled, audit committee takes over, articles and systems modified for improved governance.

Globalization & Subsidiary Expansion

• European subsidiary (EUR 25,000), Middle East subsidiary (AED 240,000), innovation/testing entities established; Hangzhou Xunqi capital increased to RMB 15 million.
• Invested HKD 12 million in Yiling Tech (10% stake), expanding global tech footprint.

Potential Price-sensitive Matters for Investors

• Expansion into X-ray Testing: Official entry and product matrix development may significantly broaden business scope and drive future growth.
• Continued Strong Performance: Revenue, profit, and cash flow all up sharply, indicating strong demand and competitiveness.
• Equity Incentives & Governance Optimization: Incentive plan stabilizes and motivates core team; governance improves transparency and efficiency.
• Accelerated Globalization: Subsidiary setup and overseas investment drive internationalization and open new markets.

Conclusion

Guangzhou Doppler’s 2025 annual report demonstrates sustained technology innovation in ultrasonic and X-ray testing, robust financial growth, governance optimization, and global expansion. The official entry into X-ray testing, strong performance, equity incentives, management changes, and globalization are all highly noteworthy and potentially price-moving events for investors.

Investors should pay close attention to progress in X-ray testing product delivery, ongoing financial growth, governance changes, and globalization—all key drivers for future value.

Disclaimer

This article is based on the company’s annual report summary and is for reference only. It does not constitute investment advice; investors should make prudent decisions and pay attention to company announcements and associated risks.

View 多浦乐 Historical chart here